Pharmacoproteomics and Cancer Management

Proteomics is a field that was initiated by Marc Wilkins in 1995 and has become an essential aspect of various scientific disciplines, particularly in medicine and oncology. Pharmacoproteomics, an extension of proteomics, is set to transform drug discovery, development, and personalized cancer therapy. Pharmacoproteomics examines protein expression patterns, post-translational modifications, and interactions to gain insights into diseases and therapeutic targets. The vital role of pharmacoproteomics in cancer management, outlining its contributions to biomarker discovery, targeted therapies, drug resistance mechanisms, and individualized treatment strategies. Utilizing high-throughput proteomic profiling, pharmacoproteomics can help identify predictive biomarkers, unravel drug mechanisms of action, and monitor treatment response and toxicity in cancer patients. This paper discusses the basic techniques of pharmacoproteomics, including mass spectrometry, gel-based, and gel-free methodologies. It highlights their applications in cancer research and drug development. Integrating pharmacoproteomics into cancer therapy can usher in a new era of precision oncology, customized to the unique molecular profiles of individual patient’s tumors, and improve treatment outcomes and patient care.